Pharmaceuticals company RPG Life Sciences announced Q2FY27 results Consolidated Financial Highlights: Revenue from operations: In Q2FY27, revenue recorded was Rs 21,164 lakh, showing an increase of 8.15% QoQ from Rs 19,569 lakh in Q1FY27 and a growth of 16.49% YoY against Rs 18,168 lakh in Q2FY26. For H1FY27, operational revenue stood at Rs 40,733 lakh, reflecting a 16.18% YoY rise over Rs 35,060 lakh in H1FY26. Total income: For Q2FY27, total income came in at Rs 21,590 lakh, jumping 8.03% QoQ from Rs 19,985 lakh in Q1FY27 and scaling 15.94% YoY against Rs 18,622 lakh in Q2FY26. For H1FY27, total income posted was Rs 41,575 lakh, higher by 15.37% YoY compared to Rs 36,037 lakh in H1FY26. Profit before tax (PBT): For Q2FY27, PBT registered at Rs 3,704 lakh, lower by 10.14% QoQ compared to Rs 4,122 lakh in Q1FY27 and a decline of 25.10% YoY relative to Rs 4,945 lakh in Q2FY26. For H1FY27, PBT printed at Rs 7,825 lakh, marking a 7.81% YoY decrease from Rs 8,488 lakh in H1FY26. Profit after tax (PAT): For Q2FY27, PAT recorded was Rs 2,822 lakh, reflecting a contraction of 7.72% QoQ against Rs 3,058 lakh in Q1FY27 and down 23.42% YoY compared to Rs 3,685 lakh in Q2FY26. For H1FY27, PAT landed at Rs 5,879 lakh, showing a decline of 6.89% YoY from Rs 6,314 lakh in H1FY26. Earnings Per Share (EPS): Basic and diluted EPS for Q2FY27 stood at Rs 17.07, declining 7.68% QoQ from Rs 18.49 in Q1FY27 and down 23.38% YoY from Rs 22.28 in Q2FY26. For H1FY27, basic and diluted EPS was recorded at Rs 35.55, lower by 6.89% YoY from Rs 38.18 in H1FY26. Standalone Financial Highlights: Revenue from operations: Standalone revenue for Q2FY27 was Rs 19,339 lakh, down 1.18% QoQ from Rs 19,569 lakh in Q1FY27 but up 6.45% YoY relative to Rs 18,168 lakh in Q2FY26. For H1FY27, standalone revenue grew by 10.98% YoY to Rs 38,908 lakh from Rs 35,060 lakh in H1FY26. Total income: For Q2FY27, standalone total income registered at Rs 19,716 lakh, decreasing 1.35% QoQ against Rs 19,985 lakh in Q1FY27 but showing a growth of 5.87% YoY from Rs 18,622 lakh in Q2FY26. For H1FY27, total income scaled by 10.17% YoY to Rs 39,701 lakh compared to Rs 36,037 lakh in H1FY26. Profit before tax (PBT): Standalone PBT reached Rs 3,008 lakh in Q2FY27, sliding 27.01% QoQ from Rs 4,121 lakh in Q1FY27 and decreasing 39.17% YoY relative to Rs 4,945 lakh in Q2FY26. For H1FY27, standalone PBT recorded was Rs 7,129 lakh, marking a 16.01% YoY drop against Rs 8,488 lakh in H1FY26. Profit after tax (PAT): For Q2FY27, standalone PAT dropped 23.81% QoQ to Rs 2,329 lakh from Rs 3,057 lakh in Q1FY27 and down 36.80% YoY compared to Rs 3,685 lakh in Q2FY26. For H1FY27, PAT stood at Rs 5,386 lakh, highlighting a 14.69% YoY decrease from Rs 6,314 lakh in H1FY26. Earnings Per Share (EPS): Basic and diluted standalone EPS for Q2FY27 was Rs 14.08, falling 23.85% QoQ compared to Rs 18.49 in Q1FY27 and dropping 36.80% YoY from Rs 22.28 in Q2FY26. For H1FY27, basic and diluted standalone EPS logged at Rs 32.57, recording a 14.70% YoY reduction from Rs 38.18 in H1FY26. Ashok Nair, Managing Director, RPG Life Sciences, said: “We have delivered another strong quarter with 16.5% revenue growth and 15% adjusted EBITDA growth, while maintaining healthy margins despite external cost pressures. More importantly, the quality of growth remains strong. Domestic Formulations continues to outperform the market, supported by volume growth, specialty therapies and new launches, while our API base business recorded significant growth during the quarter. The creation of RPG Active Pharma and the acquisitions of Actis and Raghava mark an important step in our API strategy. With the transactions completed, our focus is now on integration and value creation through higher asset utilization, deeper customer engagement, international expansion, and cost improvement. Going forward, we will continue to strengthen Domestic Formulations, build a more competitive International Formulations business, and systematically scale the expanded API business. These priorities give us a clear path to sustained and profitable growth.” Result PDF